Related Experiment Video
Updated: May 17, 2026
11:49
Quantitative Proteomics Workflow using Multiple Reaction Monitoring Based Detection of Proteins from Human Brain Tissue
Published on: August 28, 2021
Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and
Ann C Kroksveen1, Elise Aasebø, Heidrun Vethe
1Proteomics Unit (PROBE), Department of Biomedicine, University of Bergen, Bergen, Norway. ann.kroksveen@med.uib.no
Journal of Proteomics
|October 13, 2012
Summary
Researchers identified key cerebrospinal fluid (CSF) proteins that differ between early multiple sclerosis (MS) patients and controls. These findings may lead to new diagnostic biomarkers for MS.
Area of Science:
- Neuroscience
- Biochemistry
- Proteomics
Background:
- Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
- Early diagnosis and prognosis of MS are crucial for effective management.
- Cerebrospinal fluid (CSF) proteome analysis offers potential for identifying MS biomarkers.
Purpose of the Study:
- To discover and verify proteins in CSF with differential abundance between early MS patients and controls.
- To assess the potential of identified proteins as diagnostic or prognostic biomarkers for MS.
Main Methods:
- Proteomic analysis using iTRAQ and Orbitrap Mass Spectrometry (MS) to compare CSF proteomes.
- Selected Reaction Monitoring (SRM) for initial verification of candidate proteins in a larger cohort.
- Comparison of protein abundance in patients with clinically isolated syndrome (CIS), relapsing-remitting MS, and controls.
Main Results:
- Over 1200 proteins were identified in CSF.
- Five proteins showed significant abundance differences between early MS patients and controls in the initial proteomic analysis.
- Initial verification identified 11 proteins with significant abundance differences, including alpha-1-antichymotrypsin, contactin-1, apolipoprotein D, clusterin, and kallikrein-6.
Conclusions:
- This study identified several candidate CSF proteins for potential MS biomarker development.
- Further validation in larger cohorts is necessary to confirm the diagnostic and prognostic relevance of these proteins for multiple sclerosis.
